

National Cancer Institute: Connections with Commercial Partners for Technology Development.

B. Gabrielsen^a, K. Carroll^b, T. Stackhouse^a, H. Symonds^b, S. Amoroso^b, K. Maurey^b and K. Sybert^b.

^aTechnology Development & Commercialization Branch (TDCB), National Cancer Institute-Frederick Cancer Research & Development Center (NCI-FCRDC);

^bTDCB, NCI-Bethesda;

The Technology Development and Commercialization Branch (TDCB) of the National Cancer Institute (NCI) negotiates Cooperative Research and Development Agreements (CRADAs) with commercial partners to facilitate the development and utilization of new technologies emanating from the NCI programs and laboratories. This poster provides a brief but representative composite of successful antiviral collaborations from the NCI Divisions of: Basic Sciences (DBS), Clinical Sciences (DCS), and Cancer Treatment and Diagnosis (DCTD) including the Developmental Therapeutics Program (DTP). New cooperative research (CRADA) opportunities with NCI scientists will also be presented.